Table 2.
Treatment characteristics for the global cohort (training and test)
| Characteristic | All (n = 925) | United States (n = 410) | Australia (n = 68) | Brazil (n = 138) | South Korea (n = 123) | South Africa (n = 19) | Saudi Arabia (n = 13) | Japan (n = 38) | Italy (n = 41) | India (n = 75) | P value∗ |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Relapsed | 468 (51) | 258 (63) | 26 (39) | 39 (28) | 63 (52) | 6 (32) | 2 (17) | 15 (39) | 10 (24) | 49 (65) | <.001 |
| Primary refractory | 452 (49) | 151 (37) | 40 (61) | 99 (72) | 59 (48) | 13 (68) | 10 (83) | 23 (61) | 31 (76) | 26 (35) | |
| Not available | 5 | 1 | 2 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | |
| First-line therapy | |||||||||||
| Treatment, n (%) | |||||||||||
| CHOP based | 320 (35) | 132 (32) | 30 (47) | 35 (26) | 76 (62) | 5 (26) | 3 (23) | 7 (18) | 11 (27) | 21 (28) | <.001† |
| CHOEP based | 269 (29) | 140 (34) | 18 (28) | 66 (49) | 4 (3) | 13 (68) | 3 (23) | 0 | 18 (44) | 7 (9) | <.001† |
| EPOCH based | 48 (5) | 38 (9) | 1 (2) | 5 (4) | 3 (2) | 0 | 0 | 1 (3) | 0 | 0 | - |
| CHP-BV based | 19 (2) | 14 (3) | 0 | 1 (1) | 0 | 0 | 3 (23) | 0 | 1 (2) | 0 | - |
| Alemtuzumab based | 15 (2) | 14 (3) | 0 | 0 | 0 | 0 | 1 (8) | 0 | 0 | 0 | - |
| Other‡ | 248 (27) | 72 (18) | 15 (23) | 29 (21) | 40 (33) | 1 (5) | 3 (23) | 30 (79) | 11 (27) | 47 (63) | <.001† |
| NA | 6 | 0 | 4 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Treatment response, n (%) | |||||||||||
| Complete response | 410 (45) | 218 (55) | 22 (33) | 39 (28) | 49 (40) | 6 (32) | 2 (17) | 15 (39) | 13 (32) | 46 (61) | <.001† |
| Partial response | 161 (18) | 34 (9) | 18 (27) | 35 (25) | 29 (24) | 8 (42) | 10 (83) | 10 (26) | 7 (17) | 10 (13) | |
| Stable disease | 36 (4) | 17 (4) | 7 (11) | 1 (1) | 4 (3) | 2 (11) | 0 | 2 (5) | 3 (7) | 0 | |
| Progressive disease | 298 (33) | 125 (32) | 19 (29) | 63 (46) | 40 (33) | 3 (16) | 0 | 11 (29) | 18 (44) | 19 (25) | |
| NA | 20 | 16 | 2 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | |
| Underwent auto-HSCT consolidation, n (%) | 186 (21) | 122 (30) | 6 (19) | 11 (8) | 32 (26) | 2 (11) | 5 (50) | 0 | 7 (17) | 1 (2) | <.001† |
| Not available | 50 | 1 | 36 | 0 | 1 | 0 | 3 | 0 | 0 | 9 | |
| Received radiation in first line, n (%) | 121 (14) | 35 (10) | 6 (9) | 19 (14) | 32 (26) | 1 (5) | 5 (62) | 2 (5) | 1 (2) | 20 (27) | <.001† |
| NA | 70 | 64 | 0 | 0 | 0 | 0 | 5 | 0 | 0 | 1 | |
| Second-line therapy | |||||||||||
| Commonly used therapy, n (%) | <.001† | ||||||||||
| SA | 323 (35) | 219 (53) | 24 (35) | 9 (7) | 18 (15) | 1 (5) | 1 (8) | 9 (24) | 13 (32) | 29 (39) | |
| CC | 559 (60) | 154 (38) | 43 (63) | 125 (91) | 104 (85) | 18 (95) | 12 (92) | 29 (76) | 28 (68) | 46 (61) | |
| Both | 11 (1) | 5 (1) | 1 (1) | 4 (3) | 1 (1) | 0 | 0 | 0 | 0 | 0 | |
| Excluded§ | 32 (3) | 32 (8) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Achieved complete remission, n (%) | 258 (35) | 137 (39) | 18 (35) | 24 (29) | 31 (28) | 8 (57) | 4 (44) | 6 (16) | 9 (22) | 21 (45) | |
| NA | 180 | 58 | 16 | 56 | 13 | 5 | 4 | 0 | 0 | 28 | .008† |
| Underwent HSCT consolidation, n (%) | 159 (20) | 91 (23) | 13 (38) | 19 (14) | 18 (21) | 6 (33) | 0 | 3 (8) | 7 (17) | 2 (4) | |
| NA | 114 | 12 | 34 | 0 | 36 | 1 | 7 | 0 | 0 | 24 | <.001† |
| Auto-HSCT | 78 (49) | 27 (30) | 11 (85) | 15 (79) | 13 (72) | 3 (50) | 0 | 2 (67) | 6 (86) | 1 (50) | |
| Allo-HSCT | 81 (51) | 64 (70) | 2 (15) | 4 (21) | 5 (28) | 3 (50) | 0 | 1 (33) | 1 (14) | 1 (50) | <.001† |
| Total no. of lines of therapy, median (IQR) | 3 (2-4) | 3 (2-4) | 3 (3-4) | 2 (2-2) | 3 (2-4) | 2 (2-3) | 2 (2-3) | 2 (2-3) | 4 (3-5) | 2 (2-3) | <.001 |
| Year of start date, n (%) | <.001† | ||||||||||
| 2010 | 7 (1) | 4 (1) | 1 (2) | 0 | 0 | 0 | 2 (5) | 0 | 0 | ||
| 2011 | 24 (3) | 19 (5) | 2 (3) | 0 | 1 (5) | 0 | 1 (3) | 1 (2) | 0 | ||
| 2012 | 49 (6) | 39 (10) | 5 (8) | 0 | 0 | 0 | 3 (8) | 1 (2) | 1 (1) | ||
| 2013 | 47 (6) | 29 (7) | 3 (5) | 8 (7) | 1 (5) | 0 | 2 (5) | 1 (2) | 3 (4) | ||
| 2014 | 65 (9) | 42 (11) | 5 (8) | 8 (7) | 4 (21) | 0 | 1 (3) | 2 (5) | 3 (4) | ||
| 2015 | 58 (8) | 29 (7) | 5 (8) | - | 11 (9) | 2 (11) | 0 | 3 (8) | 1 (2) | 7 (9) | |
| 2016 | 74 (10) | 33 (8) | 1 (2) | 18 (15) | 2 (11) | 1 (11) | 6 (16) | 2 (5) | 11 (15) | ||
| 2017 | 108 (14) | 47 (12) | 9 (14) | 26 (21) | 2 (11) | 3 (33) | 7 (18) | 1 (2) | 13 (17) | ||
| 2018 | 88 (12) | 40 (10) | 10 (16) | 19 (15) | 1 (5) | 0 | 4 (11) | 7 (17) | 7 (9) | ||
| 2019 | 93 (12) | 30 (8) | 15 (24) | 13 (11) | 2 (11) | 2 (22) | 6 (18) | 9 (22) | 15 (20) | ||
| 2020 | 84 (11) | 41 (10) | 6 (10) | 15 (12) | 4 (21) | 1 (11) | 2 (5) | 8 (20) | 7 (9) | ||
| 2021 | 50 (7) | 35 (9) | 1 (2) | 4 (3) | 0 | 2 (22) | 0 | 5 (12) | 3 (4) | ||
| 2022 | 16 (2) | 7 (2) | 0 | 1 (1) | 0 | 0 | 0 | 3 (7) | 5 (7) | ||
| NA | 162 | 15 | 5 | 138 | 0 | 0 | 4 | 0 | 0 | 0 |
Exhibited characteristics apply to the entire global data set of 925 patients.
CHP-BV, cyclophosphamide + doxorubicin + prednisone + brentuximab; NA, information not available.
P values for the comparison between patients in different national cohorts were calculated using χ2 tests for categorical variables.
P values based on Fisher exact test due to some small cell counts.
Lymphoma subtypes for the patients receiving “other” first-line therapies include PTCL-NOS (n = 94), ENKTCL (n = 70), AITL (n = 49), ALK– ALCL (n = 23), ATLL (n = 13), HSTCL (n = 10), T-PLL (10), ALK+ALCL (n = 6), other (n = 6), and EATL (n = 5).
Patients receiving the following therapies as second line were excluded from various subanalyzes comparing effects of SA with those of CC: bexarotene, investigational study drug, methotrexate, and allo-HSCT.